Bioseal Dural Sealing Study BIOS-14-001

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

September 20, 2019

Study Completion Date

September 20, 2019

Conditions
Benign TumorsMalignant TumorsVascular Malformation
Interventions
BIOLOGICAL

Bioseal

Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.

Trial Locations (10)

100053

Xuanwu Hospital Capital Medical University, Beijing

130021

The First Hospital of Jilin University, Changchun

200040

Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai

215006

The First Affiliated Hospital of Soochow University, Suzhou

221000

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

430030

TongJi Hospital, TongJi Medical College of HUST, Wuhan

510280

ZhuJiang Hospital of Southern Medical University, Guangzhou

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

Unknown

The first Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Guangzhou Bioseal Biotechnology Co., Ltd.

INDUSTRY

NCT03110783 - Bioseal Dural Sealing Study BIOS-14-001 | Biotech Hunter | Biotech Hunter